Article Text
Statistics from Altmetric.com
Footnotes
Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.
Contributors Both authors contributed equally to the writing of this article.
Funding ARL is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology.
Competing interests ARL has received speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens-Cilag Ltd, Clinigen, Eli Lily, Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA and Heartfelt Technologies Ltd.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; externally peer reviewed.
Author note References which include a * are considered to be key references.